Matheson recently advised San Diego based Zavante Therapeutics on its acquisition by Irish registered, NASDAQ listed, Nabriva Therapeutics plc. in a deal that involved the issuance of upfront consideration in the form of Nabriva shares.

Nabriva is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections.

Zavante is a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.

Zavante was advised by a Matheson team which included Corporate M&A Partners, Fergus Bolster and Patrick Spicer, West Coast based Tax Partner, Mark O’Sullivan and Tax Senior Associate, Vahan Tchrakian.

Fergus Bolster said:

“We are very pleased to have acted, in conjunction with US advisers, for Zavante on this latest M&A transaction in the pharmaceuticals space. We, at Matheson, have particular expertise advising in relation to M&A and capital markets transactions involving equity issuances by Irish companies with US listings, and how to navigate the complexities where Irish and US securities and tax laws intersect.”

With a wealth of experience across our five partner led offices worldwide and a dedicated 100 person Corporate Department, Matheson has some of the most experienced corporate lawyers in Ireland and were named Ireland M&A Legal Adviser of the Year at the 2017 Mergermarket European M&A Awards. Excellence matters and Matheson’s Corporate Department, led by 20 partners, has unparalleled experience in complex and innovative domestic and international corporate transactions across all industry sectors.